Detailed Narrative
Q4 FY26 Financial Performance and Full Year Overview
Zensar Technologies reported Q4 FY26 revenues of $158.4 million, reflecting a 1% year-over-year growth but a sequential decline of 1.3% in reported currency. In constant currency terms, the sequential de-growth was 1.9%. For the full year FY26, the company posted revenues of $643.7 million, a 3.1% year-over-year growth in reported currency, translating to 7.7% in INR terms. The Q4 PAT margin stood at 14.4%, expanding by 50 bps sequentially, while the annual PAT for FY26 improved to $87.2 million, a 13.6% YoY growth.
Record Order Book and Large Deal Impact
The company achieved an all-time high order book of $401.8 million in Q4 FY26, representing a significant 122.9% sequential growth. This was primarily driven by a strategic large deal win, which had a gross value of $210 million and a net value of $195 million. Management indicated that while some revenue from this large deal is expected in Q1 FY27, the full-fledged revenue recognition is anticipated by Q3 FY27. The order booking, excluding this large deal, was still healthy at approximately $206 million.
AI-Native Strategy and Workforce Transformation
Zensar has made substantial investments in AI, with 85% of its workforce now AI-certified, marking a 136% increase in AI learning hours per person in FY26 compared to FY25. The company has rethought all its service lines to be AI-native and is embedding AI in every engagement, driving accelerated technology modernization. New AI-led offerings include Agentic foundry, Quality intelligence, Context intelligence, FinOps for AI, and ZenseAI.Guidewire. Internally, AI is being infused across support functions like HR (AI-enabled recruitment) and Finance (AI in AR/AP and SG&A).
Vertical Performance and Headwinds
For FY26, Banking and Financial Services grew by 11.4%, and Healthcare and Life Sciences grew by 8%. However, Manufacturing and Consumer services declined by 0.6%, and Telecom, Media, and Technology (TMT) saw a significant decline of 9.7%. Management noted that the TMT sector, particularly a top client account, will remain under pressure for the next few quarters due to in-sourcing and cost-cutting. Healthcare and Life Sciences are hoped to remain at least flat in FY27, following some consolidation plays.
Margin Outlook and Cost Pressures
Q4 FY26 EBITDA contracted by 130 bps sequentially, primarily due to lower volumes (0.3%), reversal of Q3 leave utilization benefits (1.1%), and initial costs for large deal implementation and SG&A (1.1%), partially offset by a positive forex impact (1.2%). Management anticipates continued margin pressure in Q1 and Q2 FY27 as costs associated with the large deal ramp-up, including hiring, will increase before revenue fully materializes. The overall margin guidance for FY27 is to maintain mid-teens profitability.
Talent Management and Operational Efficiency
Zensar's utilization rate improved to 84.3% in Q4, an 80 basis point sequential increase. The company made a gross addition of 968 employees during the quarter. Voluntary attrition remained at an industry-leading 9.8%, marking the fifth successive quarter below 10%, demonstrating strong talent retention. The share of revenue from service lines increased to 71.6% in Q4, up 440 basis points year-over-year, indicating a shift towards higher-value offerings.